Qiming Venture Partners Selected for China Fund Times Second Annual Private Equity and Venture Capital Yinghua Demonstration Cases
The awards aim to establish industry benchmarks for venture capital and private equity, broaden public awareness of equity investment, and promote the sector's standardized development.
Recently, the second annual China Private Equity and Venture Capital Yinghua Demonstration Awards were officially announced. Hosted by China Fund News, the awards aim to establish industry benchmarks for venture capital and private equity investment, raise public awareness of equity investment, and promote standardized industry development.
Qiming Venture Partners won awards for Top 50 Comprehensive Strength, Outstanding Exit Performance, AI Sector Investment, and Healthcare Sector Investment.
Qiming Venture Partners
Awarded
Top 50 Comprehensive Strength
Outstanding Exit Performance
AI Sector Investment
Healthcare Sector Investment
Source | China Fund News
Past Coverage
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in early and growth-stage companies in technology and healthcare innovation.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies. More than 210 of these have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many companies in Qiming's portfolio have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ: WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.